April 1, 2025
A New York federal court refused a bid from Takeda Pharmaceuticals Co. to escape a long-running case accusing it of unlawfully delaying generic versions of its diabetes treatment Actos and scheduled a trial to start in July.
U.S. District Judge Ronnie Abrams issued an opinion and order on Monday denying Takeda’s motion for summary judgment while partially granting a summary judgment motion from the buyers.
The judge also issued a separate order Monday scheduling the case for trial starting on July 21, but said the trial could be adjourned if the Second Circuit has not yet ruled on a petition from Takeda seeking an immediate appeal.
The case traces back to 2013 and has already taken two trips to the appeals court. Certified classes of direct purchasers and end payors have accused Takeda of violating antitrust law by “misdescribing” its patent rights to the U.S. Food and Drug Administration, delaying the launch of generic versions of Actos and causing inflated prices.
. . .
The end payors are represented by Hilliard Shadowen LLP, Miller Shah LLP, Wexler Boley & Elgersma LLP, Motley Rice LLC and Cohen Milstein Sellers & Toll PLLC.
Read Takeda Antitrust Trial Over Actos Generics Set for July.